Gilead Sciences’ Executive Vice President Kevin Young Appointed a Commander of the Most Excellent Order of the British Empire
June 13 2011 - 8:30AM
Business Wire
Gilead Sciences, Inc. (Nasdaq:GILD) is pleased to announce that
Kevin Young, Executive Vice President of Commercial Operations, has
been appointed a Commander of The British Empire, one of Great
Britain’s highest civilian honors, in recognition of his “services
to the healthcare and pharmaceutical industries, particularly to
the development and marketing of life-changing medicines.”
Mr. Young is a 28-year veteran of both the pharmaceutical and
biotech industries, with a distinguished career that spans a
variety of therapeutic categories including cardiology, oncology,
rheumatology, hepatitis and HIV/AIDS. He joined Gilead in 2004
after having worked for Amgen, Inc. and AstraZeneca (formerly ICI
Pharmaceuticals).
“It is a wonderful and surprising honor to receive this
appointment,” said Mr. Young. “I have been lucky to work in such a
superb industry and be involved in medicines that make a difference
in peoples’ lives. I am indebted to the colleagues I have worked
with in my career, none more so than my brilliant co-workers and
friends at Gilead Sciences, a company that has done so much to
change the face of HIV around the world.”
The Order of the British Empire recognizes distinguished service
to the arts and science, public services outside the Civil Service
and work with charitable and welfare organizations of all kinds. It
was created in the First World War in 1917 by George V. Today, the
Order of the British Empire is the order of chivalry of British
democracy. Valuable service is the only criterion for the award,
and the Order is now used to reward service in a wide range of
useful activities. An individual who is appointed “CBE” receives
their award from The Queen or The Prince of Wales at an investiture
at Buckingham Palace.
“This award is a unique privilege and a tremendous honor that is
bestowed on a very select group of individuals,” said John C.
Martin, PhD, Chairman and CEO, Gilead Sciences. “We are pleased to
congratulate Kevin on this prestigious accomplishment, which is an
acknowledgment of his numerous contributions to the field of
medicine.”
Mr. Young has undergraduate and graduate degrees in Sports
Science and Exercise from Liverpool John Moores University and
Nottingham University in England and has completed the Executive
Program at the University of Michigan. He is a member of the board
of ReSurge, the first international humanitarian organization to
provide free reconstructive plastic surgery in developing
countries.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of
unmet medical need. The company’s mission is to advance the care of
patients suffering from life-threatening diseases worldwide.
Headquartered in Foster City, California, Gilead has operations in
North America, Europe and Asia Pacific.
For more information on Gilead Sciences, please
visit the company's website at www.gilead.com or call Gilead Public
Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2024 to Jun 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jun 2023 to Jun 2024